Process Improvements of Prasugrel Hydrochloride: An Adenosine Diphosphate Receptor Antagonist

Abstract

An improved process for the synthesis of prasugrel hydrochloride with an overall yield of 58%, 99.9% purity, and meeting all other quality requirements is described.

Design, Synthesis and Pharmacological Evaluation of Novel Piperlongumine derivatives as Potential Antiplatelet Aggregation Candidate

“…Thienopyridines, including ticlopidine, clopidogrel, prasugrel, (Figure ) are wildly used in clinical for treating platelet aggregation by selectively blocking the binding of adenine diphosphate (ADP)‐induced platelet aggregation . Currently, dual treatment with aspirin and clopidogrel is the ideal treatment of antiplatelet therapy for patients with acute coronary syndromes (ACS) and prevention of thrombotic events after percutaneous coronary intervention (PCI) with stenting .…”

Synthesis of Novel Dihydropyridothienopyrimidin-4,9-dione Derivatives

“…Much attention has been paid to the thienopyrimidine and thienopyridine scaffolds due to their notable biological and pharmacological activities (Figure 1) [1,2,3,4,5,6]. Thienopyrimidines, like ( R )- N -(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(pyrrolidin-2-ylethynyl)thieno[3,2-d]pyrimidin-4-amine and 6-(1-benzyl-1 H -indol-3-yl)-2-(piperidin-1-ylmethyl)thieno[3,2-d]pyrimidin-4(3 H )-one, show potent anticancer activity by inhibition of epidermal growth factor receptor (EGFR) [1] and vascular endothelial growth factor receptor-2 (VEGFR-2) [2], respectively.…”

“…Thienopyrimidines, like ( R )- N -(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(pyrrolidin-2-ylethynyl)thieno[3,2-d]pyrimidin-4-amine and 6-(1-benzyl-1 H -indol-3-yl)-2-(piperidin-1-ylmethyl)thieno[3,2-d]pyrimidin-4(3 H )-one, show potent anticancer activity by inhibition of epidermal growth factor receptor (EGFR) [1] and vascular endothelial growth factor receptor-2 (VEGFR-2) [2], respectively. On the other hand, thienopyridine derivatives such as ticlopidine, clopidogrel, and prasugrel block P2Y 12 receptors and thus inhibit platelet activation and aggregation [3,4,5,6].…”

Synthesis of New Thienopyridine Derivatives by a Reaction of 4‐(Methylsulfanyl)‐6,7‐dihydrothieno[3,2‐c]pyridine with Amino Acids

“…). These compounds block the P2Y 12 receptors and thus inhibit platelet activation and aggregation . Antiplatelet agents are useful in the prevention of stroke, myocardial infarction, and thrombosis .…”